ArticleEuropean journal of medical research2025
Impact of thermal ablation/cryoablation treatment on prognosis among patients with kidney cancer: a SEER database-based cohort study.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Percutaneous thermal ablation for renal cell carcinoma: a comprehensive review of current evidence and future directions.La Radiologia medica · 2026Review
- Hereditary syndromes and RCC: what radiologists need to know.Abdominal radiology (New York) · 2026Review
- Framing Surgical Decisions in Elderly Patients: Minimally Invasive Partial Versus Radical Nephrectomy for Stage I Renal Cell Carcinoma at Mid-Term Follow-Up.Journal of clinical medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRadiofrequency ablation (RFA) and cryoablation are minimally invasive treatments for renal cell carcinoma (RCC). However, their comparative efficacy remains under evaluation. This study aims to compare overall survival (OS) and cancer-specific survival (CSS) outcomes using data from the Surveillance, Epidemiology, and End Results (SEER) database.
methodsThis retrospective cohort study included patients diagnosed with T1a-bN0M0 RCC from the SEER database (2004-2018). Propensity score matching was used to control for confounders, including age, sex, and tumor characteristics. Cox proportional hazards regression was applied to assess OS and CSS.
resultsA total of 3768 patients were analyzed, including 3499 with T1a and 269 with T1b tumors. Patients aged > 65 years and those with T1b tumors exhibited significantly lower OS and CSS (P < 0.001). RFA was associated with reduced OS compared to cryoablation (P = 0.012). Multivariate analyses further confirmed that elderly patients, particularly those with T1b tumors, experienced worse OS (P = 0.0104) and CSS (P = 0.008) following RFA compared to cryoablation. Subgroup and competing risk analyses consistently demonstrated lower cumulative mortality in the cryoablation group.
conclusionsCryoablation offers superior survival outcomes compared to RFA for T1a and T1b RCC, particularly in elderly patients. These findings support cryoablation as the preferred minimally invasive treatment for early-stage kidney cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.